Phospho-ALOX5 (S523) Antibody

說(shuō)明書

中文名稱：

磷酸化-ALOX5 (S523)兔多克隆抗體
貨號(hào)：

CSB-PA008470
規(guī)格：

￥1090
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

Uniprot No.：

P09917
基因名：

ALOX5
別名：

5 Lipoxygenase antibody; 5 LO antibody; 5 LOX antibody; 5-lipoxygenase antibody; 5-LO antibody; 5-LOX antibody; 5LOX antibody; 5LPG antibody; ALOX 5 antibody; Alox5 antibody; Arachidonate 5 lipoxygenase antibody; Arachidonate 5-lipoxygenase antibody; arachidonic 5-lipoxygenase alpha-10 isoform antibody; arachidonic 5-lipoxygenase delta-10-13 isoform antibody; arachidonic 5-lipoxygenase delta-13 isoform antibody; arachidonic 5-lipoxygenase delta-p10 isoform antibody; Arachidonic acid 5 lipoxygenase antibody; Leukotriene A4 synthase antibody; LOG 5 antibody; LOG5 antibody; LOX5_HUMAN antibody; MGC163204 antibody
宿主：

Rabbit
反應(yīng)種屬：

Human,Rat
免疫原：

Synthesized peptide derived from Human 5-LO around the phosphorylation site of S523.
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

Non-conjugated
抗體亞型：

IgG
純化方式：

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

WB, ELISA

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:2000
ELISA	1:10000

Protocols：

Western Blotting (WB) Protocol
ELISA Protocol
儲(chǔ)存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

功能：

Catalyzes the oxygenation of arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate) to 5-hydroperoxyeicosatetraenoate (5-HPETE) followed by the dehydration to 5,6- epoxyeicosatetraenoate (Leukotriene A4/LTA4), the first two steps in the biosynthesis of leukotrienes, which are potent mediators of inflammation. Also catalyzes the oxygenation of arachidonate into 8-hydroperoxyicosatetraenoate (8-HPETE) and 12-hydroperoxyicosatetraenoate (12-HPETE). Displays lipoxin synthase activity being able to convert (15S)-HETE into a conjugate tetraene. Although arachidonate is the preferred substrate, this enzyme can also metabolize oxidized fatty acids derived from arachidonate such as (15S)-HETE, eicosapentaenoate (EPA) such as (18R)- and (18S)-HEPE or docosahexaenoate (DHA) which lead to the formation of specialized pro-resolving mediators (SPM) lipoxin and resolvins E and D respectively, therefore it participates in anti-inflammatory responses. Oxidation of DHA directly inhibits endothelial cell proliferation and sprouting angiogenesis via peroxisome proliferator-activated receptor gamma (PPARgamma). It does not catalyze the oxygenation of linoleic acid and does not convert (5S)-HETE to lipoxin isomers. In addition to inflammatory processes, it participates in dendritic cell migration, wound healing through an antioxidant mechanism based on heme oxygenase-1 (HO-1) regulation expression, monocyte adhesion to the endothelium via ITGAM expression on monocytes. Moreover, it helps establish an adaptive humoral immunity by regulating primary resting B cells and follicular helper T cells and participates in the CD40-induced production of reactive oxygen species (ROS) after CD40 ligation in B cells through interaction with PIK3R1 that bridges ALOX5 with CD40. Also may play a role in glucose homeostasis, regulation of insulin secretion and palmitic acid-induced insulin resistance via AMPK. Can regulate bone mineralization and fat cell differentiation increases in induced pluripotent stem cells.
基因功能參考文獻(xiàn)：
1. our work shows that ALOX5 plays a moderate anti-tumor role and functions as a drug sensitizer, with a therapeutic potential, in MLL-rearranged AML. PMID: 28500307
2. Study shows that higher COX-2 and ALOX5 expression in colorectal cancer (CRC) tissues was correlated with poorer prognosis in patients with CRC. Also, MiR-216a-3p was shown to directly bind to there 3'-UTR and inversely regulates their protein levels modulating CRC cell proliferation. PMID: 28786533
3. Indicate a potential protective role of ALOX5AP and 5-arachidonate lipoxygenase gene in diabetes type 2 pathogenesis. PMID: 29392977
4. Our data reveal that 5-LO, which is required for leukotriene production and subsequent T cell recruitment, is downregulated in TAMs through Mer tyrosine kinase-dependent recognition of apoptotic cancer cells. PMID: 29229677
5. the influence of TGFbeta/SMADs on MLL- and MLL-AF4-mediated 5-LO promoter activation PMID: 28803964
6. The knockdown of arachidonate 5-lipoxygenase (Alox5) gene can induce the decreased levels of bcl/abl mRNA and BCR/ABL fusion protein in the K562/ADM cells and increased apoptosis rate. PMID: 29169426
7. Data suggest that the co-carcinogens benzidine and hydrogen peroxide induce expression of ALOX5 mRNA and protein in tracheobronchial epithelial cells; the co-carcinogens decrease cell proliferation but enhance apoptosis, actions inhibited by knockdown of ALOX5 by RNA interference. Benzidine appears to undergo metabolic activation to benzidine diimine by ALOX5. PMID: 25001243
8. This study revealed that epistatic interaction among the ALOX5, ALOX5AP and MPO genes played a significant role in vulnerability to ischemic stroke. PMID: 29041000
9. The anticancer effects by 13'-COOHs appeared to be partially independent of inhibition of COX-2/5-LOX. Using liquid chromatography tandem mass spectrometry, we found that 13'-COOHs increased intracellular dihydrosphingosine and dihydroceramides after short-time incubation in HCT-116 cells, and enhanced ceramides while decreased sphingomyelins during prolonged treatment PMID: 27016075
10. ROS production induced by the 5-LO pathway mediates the anti-cancer effects of docosahexaenoyl ethanolamide and N-arachidonoyl-L-alanine on head and neck squamous cell carcinoma cells. PMID: 27411387
11. Specific inhibitors of COX-2 and 5-LOX decreased formation of HKD2 and HKE2 Platelets did not form HKs from exogenous 5S-hydroxyeicosatetraenoic acid, implying that COX-1 is not involved PMID: 28096231
12. The observation that the coexpression of FLAP with a subset of the 5-LOX mutants restores 5-LOX-wild-type (wt)-like levels of products formed in intact cells suggests a physical protein-protein interaction, beyond colocalization, of 5-LOX and FLAP. PMID: 26842853
13. Polymorphisms in the 5-Lipoxygenase is associated with Incident Myocardial Infarction. PMID: 27893808
14. our results define Alox5 as a key genetic effector of JAK2V617F in driving polycythemia vera PMID: 27784744
15. Adipose tissue eicosapentaenoic acid and arachidonic acid and the ALOX-5 tandem repeat polymorphism did not significantly interact to affect the risk of myocardial infarction. PMID: 28566527
16. coexpression of the isoforms inhibited or stimulated 5-LO-WT expression in transiently and stably transfected HEK293T cells suggesting that the isoforms have other functions than canonical leukotriene biosynthesis PMID: 28257804
17. a novel putative protein isoform of human 5-LO that lacks exon 4, termed 5-LODelta4, was identified. PMID: 27855198
18. Oxidative stress decreased the levels of PNPLA2 transcripts with no effect on ALOX5 expression. Exogenous additions of P1 peptide or overexpression of the PNPLA2 gene decreased both LTB4 levels and death of RPE cells undergoing oxidative stress. PMID: 27635633
19. Dimethyl ester of bilirubin exhibits anti-inflammatory activity through inhibition of secretory phospholipase A2, lipoxygenase and cyclooxygenase. PMID: 27060751
20. Copy number variation in ALOX5 is associated with NSAIDs-induced urticaria and/or angioedema. PMID: 26959713
21. This study identified a SNP (rs10507391) in ALOX5 gene as a novel genetic risk factor for Alzheimer's disease and body mass index. PMID: 26944113
22. ALOX5 gene variants do not appear to be related to clinical CHD events or subclinical atherosclerosis regardless of bioavailable enzyme substrate levels in multiethnic cohort. PMID: 27025886
23. our data suggest that the inhibition of both COX-2/5-LOX may be an effective therapeutic approach for colon cancer management, particularly for those patients with high expression of COX-2/5-LOX PMID: 26707712
24. we identified differences in the frequency distribution in the Tibetan population located in the ALOX5 , VKORC1 and PTGS2 genes PMID: 26505400
25. AF4 and AF4-MLL mediate transcriptional elongation of 5-lipoxygenase mRNA by 1, 25-dihydroxyvitamin D3. PMID: 26329759
26. the Alox-5 gene might play a role in the differentiation of multiple drug resistant and non-resistant erythroleukemic cell lines PMID: 26852002
27. These results suggest that COX-2 and 5-LO play roles in tumorigenesis and the progression of primary glioblastoma and that the co-expression pattern of COX-2/5-LO may be used as an independent prognostic factor in this disease. PMID: 26334317
28. Increased PUFA Content and 5-lipoxygenase pathway expression are associated with subcutaneous adipose tissue inflammation in obese women with type 2 diabetes. PMID: 26378572
29. The study shows that 5-lipoxygenase (5-LO) in B cells is phosphorylated on Ser523 and demonstrates for the first time a chemical difference between 5-LO in myeloid cells and B cells. PMID: 26210919
30. Study identified a novel splice variant of 5-LO consisting of 139 amino acids due to premature stop. It was found to be expressed in HepG2 cells only, raising the possibility for putative role in liver cancer development. PMID: 25218842
31. GSAP cleavage via caspase-3 is regulated and depend upon the availability of 5-Lipoxygenase in Alzheimer's disease. PMID: 26076991
32. investigated potential mechanisms by which 5-LO13 interferes with 5-LO product biosynthesis in transfected HEK293 cells PMID: 26173130
33. Two of the most potent/selective inhibitors (HIR-303 and HIR-309) were reductive inhibitors and were potent against 5-LOX in human whole blood, indicating that isoflavans can be potent and selective inhibitors against human leukocyte 5-LOX PMID: 25359714
34. The study explores the substrate access portal of 5-Lipoxygenase. PMID: 26427761
35. involvement of lipoxygenase pathways in TNF-alpha-induced production of cytokines and chemokines PMID: 25229347
36. Report no association between ALOX5 SNPs and atherosclerotic plaque phenotypes. PMID: 25721704
37. THE 5-LOX interface involving the four cysteines 159, 300, 416 and 418 is important for the translocation to the nuclear membrane and the colocalization with FLAP. PMID: 26327594
38. Genotoxic stress induces the ALOX5 mRNA and protein expression in a p53-dependent manner. PMID: 26070487
39. Results suggest that the level of 5-LOX expression was increased in pancreatic cancer tissues and may be related to lymph node metastasis and TNM stage. PMID: 25483364
40. Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia. PMID: 25193960
41. 5-LOX inhibition reduced apoptotic death, restored the initial IL-2/INF-gamma ratio, and more importantly reverted micro-calpain activation induced by simulated microgravity. PMID: 25309925
42. contributes to inflammatory microenvironment of precancerous pancreatic lesions PMID: 25454978
43. Increased metabolites of 5-lipoxygenase from hypoxic ovarian cancer cells promote tumor-associated macrophage infiltration. PMID: 24662827
44. These findings indicate that the oncogenic function of c-Myc in prostate cancer cells is regulated by 5-Lox activity, revealing a novel mechanism of 5-Lox action PMID: 25540201
45. Human cytomegalovirus (HCMV) induced up-regulation of 5-lipoxygenase in both ex vivo HCMV-infected placental explants and human umbilical vein endothelial cells (HUVEC) PMID: 24746852
46. Jurkat T cells overexpressing 5-LO failed to activate PPARgamma in macrophages, while their 5-LO overexpressing apoptotic counterparts did. PMID: 24036216
47. Polymorphisms within FLT3, EGFR, NEIL3, and ALOX5 may contribute to the occurrence of GBM. PMID: 24005813
48. 5-LO disruption improves wound healing and alters fibroblast function by an antioxidant mechanism based on HO-1 induction. PMID: 24226420
49. The changes of LTB4 concentration in serum and the mRNA expression level of 5-LO in decidua may play an important role in the success and maintenance of a healthy pregnancy. PMID: 23572152
50. The 5-LOX/LTC4 /CysLT1 signaling pathway regulates EGF-induced cell migration by increasing Tiam1 expression. PMID: 24350867
顯示更多

收起更多
亞細(xì)胞定位：

Cytoplasm. Nucleus matrix. Nucleus membrane; Peripheral membrane protein. Cytoplasm, perinuclear region. Cytoplasm, cytosol. Nucleus envelope. Nucleus intermembrane space.
蛋白家族：

Lipoxygenase family
數(shù)據(jù)庫(kù)鏈接：

HGNC: 435

OMIM: 152390

KEGG: hsa:240

STRING: 9606.ENSP00000363512

UniGene: Hs.89499

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human